Alaunos Therapeutics, Inc. (TCRT) Form 8-K — Oct 21, 2026
Alaunos Therapeutics (TCRT) says it has regained compliance with Nasdaq's $2.5 million stockholders' equity requirement following its October 2026 merger with Velaris Therapeutics and a $350.0 million private placement led by Fairmount. The company's FY2025 stockholders' equity of $2,153,000 had put it out of compliance, and a Nasdaq Hearings Panel hearing scheduled for November 10, 2026 is now expected to be cancelled once Nasdaq staff confirms the cure. A key element was a limited waiver from Fairmount Fund II on ~$9.0 million of Series C Preferred shares, ensuring those convert into common stock (counting toward permanent equity) rather than requiring cash settlement.
Key figures
- Gross Proceeds
- 350000000
- Offering Price
- 1.4357
- Shares Offered
- 687789
- Stockholders Equity
- 2153000
- Nasdaq hearing date
- 2026-11-10
- Waived shares value
- 9000000
- Deficiency letter date
- 2026-04-09
- Waived series c shares
- 6268
- Series c preferred shares sold
- 243063
- Stockholders equity requirement
- 2500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.